Sector News

Feds almost ready to charge drugmakers—and executives—in generics price-fixing probe

April 26, 2018
Life sciences

U.S. prosecutors have been digging into potential price-fixing in the generics world, and along the way, they’ve searched corporate offices and tracked executive movements at industry conferences. Now they’re close to slapping charges on two companies and several execs, Bloomberg reports.

The charges could come this summer, according to Bloomberg’s sources, but those sources didn’t disclose which companies—or executives—would be targeted.

One revelation from the reporting? The feds raided Mylan’s headquarters in September 2016 when CEO Heather Bresch was testifying to Congress about EpiPen price hikes, a source told Bloomberg.

Mylan didn’t immediately respond to a request for comment. The federal generic price-fixing investigation is separate from Mylan’s EpiPen pricing controversy, which started in 2016 and continued into 2017.

Authorities have also searched Perrigo’s offices, the company disclosed last year.

Federal authorities have been investigating possible price fixing in the generics industry for years, leading to regular disclosures by companies that they are under investigation. The government arrested former Heritage Pharma executives in late 2016 and secured a plea deal in 2017 in exchange for their cooperation with the probe.

Since then, state attorneys general—led by Connecticut AG George Jepsen—have filed a civil lawsuit against 18 companies and two executives alleging price fixing on 15 drugs. Mylan president Rajiv Malik was named as a defendant, and the company at the time said it stands by its executive.

“Mylan and Rajiv Malik both intend to defend this case vigorously, and we look forward to the opportunity to present a full defense,” the company said in a statement at the time.

In a document published alongside the lawsuit, Jepsen’s office said the original allegations are the “tip of the iceberg” of alleged pricing collusion.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.